Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: METAP2

Gene summary for METAP2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

METAP2

Gene ID

10988

Gene namemethionyl aminopeptidase 2
Gene AliasMAP2
Cytomap12q22
Gene Typeprotein-coding
GO ID

GO:0006464

UniProtAcc

P50579


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
10988METAP2AEH-subject2HumanEndometriumAEH1.83e-07-1.81e-01-0.2525
10988METAP2AEH-subject3HumanEndometriumAEH2.57e-08-1.82e-01-0.2576
10988METAP2AEH-subject4HumanEndometriumAEH4.09e-05-2.59e-01-0.2657
10988METAP2AEH-subject5HumanEndometriumAEH4.32e-03-2.64e-01-0.2953
10988METAP2EEC-subject1HumanEndometriumEEC9.56e-08-2.77e-01-0.2682
10988METAP2EEC-subject2HumanEndometriumEEC1.24e-06-1.69e-01-0.2607
10988METAP2EEC-subject3HumanEndometriumEEC1.66e-24-1.69e-01-0.2525
10988METAP2EEC-subject4HumanEndometriumEEC1.30e-10-3.56e-01-0.2571
10988METAP2EEC-subject5HumanEndometriumEEC3.97e-02-2.42e-01-0.249
10988METAP2GSM5276934HumanEndometriumEEC2.14e-031.19e-01-0.0913
10988METAP2GSM6177620_NYU_UCEC1_lib1_lib1HumanEndometriumEEC1.00e-29-1.08e-01-0.1869
10988METAP2GSM6177620_NYU_UCEC1_lib2_lib2HumanEndometriumEEC1.38e-31-5.08e-02-0.1875
10988METAP2GSM6177620_NYU_UCEC1_lib3_lib3HumanEndometriumEEC2.35e-33-1.97e-01-0.1883
10988METAP2GSM6177621_NYU_UCEC2_lib1_lib1HumanEndometriumEEC2.12e-271.96e-02-0.1934
10988METAP2GSM6177622_NYU_UCEC3_lib1_lib1HumanEndometriumEEC6.51e-39-1.66e-01-0.1917
10988METAP2GSM6177622_NYU_UCEC3_lib2_lib2HumanEndometriumEEC3.58e-44-9.72e-02-0.1916
10988METAP2GSM6177623_NYU_UCEC3_VisHumanEndometriumEEC1.27e-03-2.05e-01-0.1269
10988METAP2LZE4THumanEsophagusESCC5.02e-241.30e-010.0811
10988METAP2LZE7THumanEsophagusESCC3.35e-068.32e-010.0667
10988METAP2LZE8THumanEsophagusESCC5.09e-031.25e-010.067
Page: 1 2 3 4 5 6 7 8 9 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:005160419SkincSCCprotein maturation117/4864294/187231.27e-072.93e-06117
GO:00164858SkincSCCprotein processing79/4864225/187231.43e-039.02e-0379
GO:005160420ThyroidPTCprotein maturation132/5968294/187231.71e-062.39e-05132
GO:00164859ThyroidPTCprotein processing95/5968225/187236.60e-044.15e-0395
GO:0051604110ThyroidATCprotein maturation136/6293294/187234.00e-064.42e-05136
GO:001648515ThyroidATCprotein processing100/6293225/187234.39e-042.62e-03100
Page: 1 2 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
METAP2SNVMissense_Mutationc.758N>Tp.Gly253Valp.G253VP50579protein_codingdeleterious(0)probably_damaging(1)TCGA-A8-A06U-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
METAP2SNVMissense_Mutationrs752983315c.614G>Ap.Arg205Hisp.R205HP50579protein_codingdeleterious(0)probably_damaging(0.994)TCGA-AO-A0JC-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapyfluorouracilSD
METAP2SNVMissense_Mutationc.1051N>Ap.Glu351Lysp.E351KP50579protein_codingdeleterious(0.01)possibly_damaging(0.822)TCGA-GM-A2DO-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenCR
METAP2SNVMissense_Mutationnovelc.1253N>Ap.Arg418Lysp.R418KP50579protein_codingdeleterious(0.04)possibly_damaging(0.769)TCGA-LD-A74U-01Breastbreast invasive carcinomaFemale>=65III/IVChemotherapytaxotereSD
METAP2SNVMissense_Mutationnovelc.281N>Ap.Gly94Glup.G94EP50579protein_codingtolerated(0.28)benign(0.025)TCGA-C5-A2LZ-01Cervixcervical & endocervical cancerFemale>=65III/IVUnknownUnknownPD
METAP2SNVMissense_Mutationnovelc.797N>Tp.Thr266Ilep.T266IP50579protein_codingdeleterious(0)probably_damaging(1)TCGA-AA-3811-01Colorectumcolon adenocarcinomaFemale>=65III/IVUnknownUnknownPD
METAP2SNVMissense_Mutationnovelc.463N>Cp.Lys155Glnp.K155QP50579protein_codingdeleterious(0)benign(0.049)TCGA-AZ-4315-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
METAP2SNVMissense_Mutationc.473N>Cp.Leu158Serp.L158SP50579protein_codingdeleterious(0.02)benign(0.024)TCGA-CA-6718-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownPD
METAP2SNVMissense_Mutationc.908N>Tp.Ala303Valp.A303VP50579protein_codingdeleterious(0.05)benign(0.028)TCGA-G4-6588-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
METAP2SNVMissense_Mutationc.223G>Ap.Ala75Thrp.A75TP50579protein_codingtolerated_low_confidence(0.36)benign(0)TCGA-G4-6628-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEPPI-2458PPI-2458
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEPPI-2458PPI-2458
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEBELORANIBBELORANIB
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEBeloranibBELORANIB
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEXMT-1107
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASED-Methionine
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEinhibitorCHEMBL2103847TOSEDOSTAT
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEinhibitor252166655BELORANIB
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEinhibitor178103100
10988METAP2ENZYME, DRUGGABLE GENOME, KINASE, PROTEASEM8891
Page: 1 2